Felzartamab Proves Safety, Potential for Therapeutic Benefit on Antibody-Mediated Rejection Following Kidney Transplant hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
Biogen to Buy Human Immunology Biosciences for up to $1 8 Billion Deal usnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usnews.com Daily Mail and Mail on Sunday newspapers.
Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ. The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.
Diamond, Queller elected to National Academy of Sciences - The Source - Washington University in St Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
The Law of Return and the Zionist Campaign to Subvert Science imemc.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imemc.org Daily Mail and Mail on Sunday newspapers.